Tags

Type your tag names separated by a space and hit enter

A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B.
Am J Clin Nutr. 2017 05; 105(5):1239-1247.AJ

Abstract

Background:

Evidence from randomized controlled trials (RCTs) suggests the consumption of konjac glucomannan (KJM), a viscous soluble fiber, for improving LDL-cholesterol concentrations. It has also been suggested that the cholesterol-lowering potential of KJM may be greater than that of other fibers. However, trials have been relatively scarce and limited in sample size and duration, and the effect estimates have been inconsistent. The effect of KJM on new lipid targets of cardiovascular disease (CVD) risk is also unknown.

Objective:

This systematic review and meta-analysis aimed to assess the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.

Design:

Medline, Embase, CINAHL, and the Cochrane Central databases were searched. We included RCTs with a follow-up of ≥3 wk that assessed the effect of KJM on LDL cholesterol, non-HDL cholesterol, or apolipoprotein B. Data were pooled by using the generic inverse-variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the Cochran Q statistic and quantified by the I2 statistic.

Results:

Twelve studies (n = 370), 8 in adults and 4 in children, met the inclusion criteria. KJM significantly lowered LDL cholesterol (MD: -0.35 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19 mmol/L). Data from 6 trials suggested no impact of KJM on apolipoprotein B.

Conclusions:

Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively. The information may be of interest to health agencies in crafting future dietary recommendations related to reduction in CVD risk. This study was registered at clinicaltrials.gov as NCT02068248.

Authors+Show Affiliations

Clinical Nutrition and Risk Factor Modification Centre. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre. Toronto 3D Knowledge Synthesis and Clinical Trials Unit, St. Michael's Hospital, Toronto, Canada. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre.Clinic for Diabetes, Endocrinology and Metabolic Diseases Vuk Vrhovac, University Hospital Merkur, University of Zagreb, School of Medicine, Zagreb, Croatia; and.Clinical Nutrition and Risk Factor Modification Centre. Li Ka Shing Knowledge Institute. Division of Endocrinology and Medicine, and. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.Clinical Nutrition and Risk Factor Modification Centre, v.vuksan@utoronto.ca. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

28356275

Citation

Ho, Hoang Vi Thanh, et al. "A Systematic Review and Meta-analysis of Randomized Controlled Trials of the Effect of Konjac Glucomannan, a Viscous Soluble Fiber, On LDL Cholesterol and the New Lipid Targets non-HDL Cholesterol and Apolipoprotein B." The American Journal of Clinical Nutrition, vol. 105, no. 5, 2017, pp. 1239-1247.
Ho HVT, Jovanovski E, Zurbau A, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. Am J Clin Nutr. 2017;105(5):1239-1247.
Ho, H. V. T., Jovanovski, E., Zurbau, A., Blanco Mejia, S., Sievenpiper, J. L., Au-Yeung, F., Jenkins, A. L., Duvnjak, L., Leiter, L., & Vuksan, V. (2017). A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. The American Journal of Clinical Nutrition, 105(5), 1239-1247. https://doi.org/10.3945/ajcn.116.142158
Ho HVT, et al. A Systematic Review and Meta-analysis of Randomized Controlled Trials of the Effect of Konjac Glucomannan, a Viscous Soluble Fiber, On LDL Cholesterol and the New Lipid Targets non-HDL Cholesterol and Apolipoprotein B. Am J Clin Nutr. 2017;105(5):1239-1247. PubMed PMID: 28356275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. AU - Ho,Hoang Vi Thanh, AU - Jovanovski,Elena, AU - Zurbau,Andreea, AU - Blanco Mejia,Sonia, AU - Sievenpiper,John L, AU - Au-Yeung,Fei, AU - Jenkins,Alexandra L, AU - Duvnjak,Lea, AU - Leiter,Lawrence, AU - Vuksan,Vladimir, Y1 - 2017/03/29/ PY - 2016/08/23/received PY - 2017/02/21/accepted PY - 2017/3/31/pubmed PY - 2017/7/20/medline PY - 2017/3/31/entrez KW - CVD risk reduction KW - LDL cholesterol KW - konjac glucomannan KW - non-HDL cholesterol and apolipoprotein B KW - systematic review and meta-analysis SP - 1239 EP - 1247 JF - The American journal of clinical nutrition JO - Am J Clin Nutr VL - 105 IS - 5 N2 - Background: Evidence from randomized controlled trials (RCTs) suggests the consumption of konjac glucomannan (KJM), a viscous soluble fiber, for improving LDL-cholesterol concentrations. It has also been suggested that the cholesterol-lowering potential of KJM may be greater than that of other fibers. However, trials have been relatively scarce and limited in sample size and duration, and the effect estimates have been inconsistent. The effect of KJM on new lipid targets of cardiovascular disease (CVD) risk is also unknown.Objective: This systematic review and meta-analysis aimed to assess the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.Design: Medline, Embase, CINAHL, and the Cochrane Central databases were searched. We included RCTs with a follow-up of ≥3 wk that assessed the effect of KJM on LDL cholesterol, non-HDL cholesterol, or apolipoprotein B. Data were pooled by using the generic inverse-variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the Cochran Q statistic and quantified by the I2 statistic.Results: Twelve studies (n = 370), 8 in adults and 4 in children, met the inclusion criteria. KJM significantly lowered LDL cholesterol (MD: -0.35 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19 mmol/L). Data from 6 trials suggested no impact of KJM on apolipoprotein B.Conclusions: Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively. The information may be of interest to health agencies in crafting future dietary recommendations related to reduction in CVD risk. This study was registered at clinicaltrials.gov as NCT02068248. SN - 1938-3207 UR - https://www.unboundmedicine.com/medline/citation/28356275/A_systematic_review_and_meta_analysis_of_randomized_controlled_trials_of_the_effect_of_konjac_glucomannan_a_viscous_soluble_fiber_on_LDL_cholesterol_and_the_new_lipid_targets_non_HDL_cholesterol_and_apolipoprotein_B_ L2 - https://academic.oup.com/ajcn/article-lookup/doi/10.3945/ajcn.116.142158 DB - PRIME DP - Unbound Medicine ER -